QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:CPRX

Catalyst Pharmaceuticals Stock Forecast, Price & News

$3.52
-0.01 (-0.28 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.49
Now: $3.52
$3.69
50-Day Range
$3.49
MA: $3.95
$4.60
52-Week Range
$2.55
Now: $3.52
$5.19
Volume1.50 million shs
Average Volume1.79 million shs
Market Capitalization$364.84 million
P/E Ratio5.25
Dividend YieldN/A
Beta1.53
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Catalyst Pharmaceuticals logo

Headlines

3 Biotech Stocks on the Robinhood 100 to AVOID
January 8, 2021 |  stocknews.com
Is CPRX A Good Stock To Buy Now?
December 16, 2020 |  finance.yahoo.com
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings Estimates
November 9, 2020 |  finance.yahoo.com
Catalyst sues sellers of generic Firdapse
October 19, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CPRX
CUSIPN/A
Phone305-420-3200
Employees76
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$102.31 million
Cash Flow$0.31 per share
Book Value$0.85 per share

Profitability

Net Income$31.88 million

Miscellaneous

Market Cap$364.84 million
Next Earnings Date3/15/2021 (Confirmed)
OptionableOptionable

MarketRank

Overall MarketRank

1.72 out of 5 stars

Medical Sector

224th out of 1,971 stocks

Pharmaceutical Preparations Industry

102nd out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -
$3.52
-0.01 (-0.28 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions

Is Catalyst Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Catalyst Pharmaceuticals stock.
View analyst ratings for Catalyst Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Catalyst Pharmaceuticals?

Wall Street analysts have given Catalyst Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Catalyst Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Catalyst Pharmaceuticals' next earnings date?

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Catalyst Pharmaceuticals
.

How can I listen to Catalyst Pharmaceuticals' earnings call?

Catalyst Pharmaceuticals will be holding an earnings conference call on Monday, March 15th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its earnings results on Monday, November, 16th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.01. The biopharmaceutical company had revenue of $29.32 million for the quarter, compared to analyst estimates of $31.22 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 35.04% and a net margin of 60.48%.
View Catalyst Pharmaceuticals' earnings history
.

How has Catalyst Pharmaceuticals' stock been impacted by Coronavirus?

Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CPRX shares have increased by 0.0% and is now trading at $3.52.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CPRX?

4 brokerages have issued 1-year price objectives for Catalyst Pharmaceuticals' shares. Their forecasts range from $5.50 to $10.00. On average, they anticipate Catalyst Pharmaceuticals' stock price to reach $7.83 in the next twelve months. This suggests a possible upside of 122.5% from the stock's current price.
View analysts' price targets for Catalyst Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the following people:
  • Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 74, Pay $908.7k)
  • Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 59, Pay $643.31k)
  • Dr. Gary Ingenito, Chief Medical & Regulatory Officer (Age 65, Pay $646.75k)
  • Ms. Alicia Grande, VP, Treasurer & CFO (Age 50)
  • Mr. Brian Elsbernd J.D., Chief Legal & Compliance Officer (Age 57)
  • Mr. Pete Curry Sr., VP of Sales
  • Mr. Jeffrey Del Carmen, Chief Commercial Officer (Age 51)
  • Mr. Philip B. Schwartz, Corp. Sec. (Age 66)
  • Dr. Charles W. Gorodetzky, Consultant (Age 83)

Who are some of Catalyst Pharmaceuticals' key competitors?

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.47%), Royce & Associates LP (2.32%), HealthInvest Partners AB (1.69%), Northern Trust Corp (1.21%), Nuveen Asset Management LLC (0.88%) and Schroder Investment Management Group (0.88%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Gary Ingenito and Patrick J Mcenany.
View institutional ownership trends for Catalyst Pharmaceuticals
.

Which institutional investors are selling Catalyst Pharmaceuticals stock?

CPRX stock was sold by a variety of institutional investors in the last quarter, including Engineers Gate Manager LP, Jane Street Group LLC, Schroder Investment Management Group, Credit Suisse AG, SG Americas Securities LLC, Brandywine Global Investment Management LLC, Northern Trust Corp, and Wells Fargo & Company MN.
View insider buying and selling activity for Catalyst Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Catalyst Pharmaceuticals stock?

CPRX stock was purchased by a variety of institutional investors in the last quarter, including HealthInvest Partners AB, Royce & Associates LP, Nuveen Asset Management LLC, Globeflex Capital L P, BlackRock Inc., Prairiewood Capital LLC, Bank of New York Mellon Corp, and GSA Capital Partners LLP. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, and Patrick J Mcenany.
View insider buying and selling activity for Catalyst Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $3.52.

How much money does Catalyst Pharmaceuticals make?

Catalyst Pharmaceuticals has a market capitalization of $364.84 million and generates $102.31 million in revenue each year. The biopharmaceutical company earns $31.88 million in net income (profit) each year or $0.30 on an earnings per share basis.

How many employees does Catalyst Pharmaceuticals have?

Catalyst Pharmaceuticals employs 76 workers across the globe.

What is Catalyst Pharmaceuticals' official website?

The official website for Catalyst Pharmaceuticals is www.catalystpharma.com.

Where are Catalyst Pharmaceuticals' headquarters?

Catalyst Pharmaceuticals is headquartered at 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.